Description des résultats rapportés par les patients (PROs) à l’inclusion dans une étude de phase IV évaluant ocrelizumab dans la sclérose en plaques (SEP) récurrente active (PRO-MSACTIVE)
- DOI
- 10.1016/j.neurol.2020.01.240
- Published
- 2020-09
- Container
- Revue Neurologique
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.neurol.2020.01.240,
title = {Description des résultats rapportés par les patients (PROs) à l’inclusion dans une étude de phase IV évaluant ocrelizumab dans la sclérose en plaques (SEP) récurrente active (PRO-MSACTIVE)},
author = {Eric Manchon and David Laplaud and Sandra Vukusic and Pierre Labauge and Gisela Kobelt and Marie Lotz and Christine Lebrun-Frénay},
year = {2020},
journal = {Revue Neurologique},
doi = {10.1016/j.neurol.2020.01.240},
url = {https://doi.org/10.1016/j.neurol.2020.01.240}
}RIS
TY - JOUR TI - Description des résultats rapportés par les patients (PROs) à l’inclusion dans une étude de phase IV évaluant ocrelizumab dans la sclérose en plaques (SEP) récurrente active (PRO-MSACTIVE) AU - Eric Manchon AU - David Laplaud AU - Sandra Vukusic AU - Pierre Labauge AU - Gisela Kobelt AU - Marie Lotz AU - Christine Lebrun-Frénay PY - 2020 JO - Revue Neurologique DO - 10.1016/j.neurol.2020.01.240 UR - https://doi.org/10.1016/j.neurol.2020.01.240 ER -
APA
Manchon, E., Laplaud, D., Vukusic, S., Labauge, P., Kobelt, G., Lotz, M., & Lebrun-Frénay, C. (2020). Description des résultats rapportés par les patients (PROs) à l’inclusion dans une étude de phase IV évaluant ocrelizumab dans la sclérose en plaques (SEP) récurrente active (PRO-MSACTIVE). Revue Neurologique. https://doi.org/10.1016/j.neurol.2020.01.240
Source records
- crossref · retrieved 2026-09-26T18:00:46.395Z